Remifentanil pretreatment ameliorates H/R-induced cardiac microvascular endothelial cell dysfunction by regulating the PI3K/Akt/HIF-1α signaling pathway

Xiaojun Li, Zhenping Gui, Huizi Liu, Shaojie Qian, Yanan Jia, and Xiaopan Luo

ABSTRACT
Restoration of blood supply through medical or surgical intervention is a commonly adopted method for acute myocardial ischemia, but is also a trigger for cardiac ischemia/reperfusion injury. Studies have shown that remifentanil (REM) displays cardioprotective effects. In this study, the effects of REM on HCMEC viability were examined before and after the induction of H/R using Cell Counting Kit-8 assays. Wound healing and Matrigel angiogenesis assays were performed to assess HCMEC migration and angiogenesis, respectively. Commercial kits and western blotting were used to determine the endothelial barrier function of H/R-stimulated HCMECs with or without REM treatment. The expression of PI3K/Akt/hypoxia-inducible factor-1α (HIF-1α) pathway-related proteins was detected by western blotting. After pre-treatment with PI3K/Akt, the effects of REM on H/R-induced HCMEC injury were examined. We found that pre-treatment with REM displayed no impact on HCMEC viability under normal conditions but noticeably improved cell viability following H/R. The migratory abilities and tube-like structure formations of H/R-stimulated HCMECs were both enhanced by REM in a concentration-dependent manner. REM also decreased the permeability of H/R-stimulated HCMECs and upregulated the expression of tight junction proteins. Furthermore, REM increased the expression of PI3K/Akt/HIF-1α signaling-related proteins in HCMECs. Inhibition of PI3K/Akt rescued REM-enhanced HCMEC function under H/R condition. Therefore, the present study demonstrated that REM pretreatment ameliorated H/R-induced HCMEC dysfunction by regulating the PI3K/Akt/HIF-1α signaling pathway.

CONTACT Xiaopan Luo luoxiap12@163.com Department of Anesthesiology, Zhejiang Provincial People’s Hospital, 158 Shangtang Road, Xiacheng District, Hangzhou City, Zhejiang Province, 310000, P.R. China

ARTICLE history
Received 8 July 2021
Revised 12 August 2021
Accepted 14 August 2021

KEYWORDS
Remifentanil; myocardial ischemia; hypoxia/reoxygenation; PI3K/Akt/HIF-1α; cardiac microvascular endothelial cells

Introduction
Myocardial ischemia is a pathophysiological condition in which the coronary artery is deficient in blood and oxygen supply to the myocardium due to coronary artery stenosis (primarily caused by atherosclerosis), spasm or embolism [1,2]. In numerous pathological processes leading to heart failure, myocardial ischemia displays the highest prevalence and, thus, represents a serious danger to the health of patients with cardiovascular diseases [3]. As for current therapeutic strategies for myocardial ischemia, treatment in the acute phase promotes the rapid release of the ischemic condition, such as improvement of myocardial blood and oxygen supply using drugs that dilate the coronary artery (e.g., nitroglycerin) or coronary recanalization by minimally invasive or surgical procedures [4]. Although coronary reperfusion therapy effectively reduces myocardial ischemic injury and prevents further tissue damage, cases of reperfusion injury are not clinically rare and occur due to free radical formation, activation of autophagy, calcium overload and neutrophil infiltration into the infarct zone during the process [5–7]. Besides these factors, other physiological processes implicated in the mechanism underlying reperfusion injury are still being explored. Cardiac ischemia/reperfusion (I/R) injury impairs endothelial barrier function, increases endothelial permeability and causes cell swelling, leading to microthrombosis and microvascular obstruction that block the blood supply to the heart [8–10]. Therefore, effective management of I/R injury is important for the treatment of myocardial ischemia.

Remifentanil (REM), a mu-opioid receptor agonist of fentanyl, can quickly reach the blood-brain
barrier in the human body and is mostly used as an intra-operative analgesic [11]. Studies suggest that REM may display cardioprotective effects, in that concomitant use of REM in patients undergoing cardiac surgery has been clinically shown to be associated with reduced cardiac troponin release, time of mechanical ventilation and length of hospital stay [12,13]. Moreover, mice preconditioned with REM have been reported to display a much lower risk of myocardial injury following I/R procedures, whereas hyperglycemia-induced oxidative stress could diminish REM cardioprotection by damaging the Caveolin-3-regulated PI3K/Akt and Janus kinase 2 (JAK2)/Stat3 signaling pathways [14]. The present study investigated a similar cardioprotective effect of REM on cardiac microvascular endothelial cells in vitro.

Based on the results of the above literature review, we speculate that REM has therapeutic effect on myocardial ischemia-reperfusion injury. Therefore, in this paper, we discussed the effect and mechanism of H/R-induced cardiac microvascular endothelial cell dysfunction. This study provides a solid theoretical basis for REM as a new adjuvant for the treatment of myocardial ischemia.

Materials and methods

Cell culture, model induction, and drug treatment

Human cardiac microvascular endothelial cells (HCMECs) were obtained from ScienCell Research Laboratories, Inc. and cultured in Endothelial Cell Medium (ScienCell Research Laboratories, Inc.) with 5 mmol/l glucose (Gibco; Thermo Fisher Scientific, Inc.) and 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO₂. To perform hypoxia/reoxygenation (H/R), HCMECs were incubated in an anaerobic chamber with 95% N₂ and 5% CO₂ at 37°C. Prior to hypoxia, the culture medium was replaced with glucose free and serum free Endothelial Cell Medium for 3 h. Then, cells were transferred to FBS-containing Endothelial Cell Medium and cultured under normal conditions for 2 h. As for REM administration, cells were pretreated with 0.625, 1.25 or 2.5 μM REM for 1 h prior to H/R stimulation. To inhibit PI3K/Akt expression, LY294002 (10 μM) was selected for pretreatment of HCMECs for 1 h prior to H/R.

Cell counting Kit-8 (CCK-8) assay

Cells (2 x 10⁴ cells/mL) were cultured in 96-well plates at 37°C. After corresponding treatments for different groups, CCK-8 reagent (Beyotime Institute of Biotechnology) was added into each well for 2 h at 37°C. The optical density was measured at a wavelength of 450 nm [15].

Wound healing assay

Cells were seeded into 12-well plates (2 x 10⁵ cells/well) and treated corresponding to each group. A scratch was made in the confluent cell monolayer using a 10-μl pipette tip. Subsequently, the cells were cultured in serum-free Endothelial Cell Medium. An inverted light microscope (Olympus Corporation; magnification, x100) was used to observe the wounds at 0 and 24 h. The wound healing rate was calculated using ImageJ software (version 1.46; National Institutes of Health). The rate of wound healing = [(the wound width of 0 h – 24 h)/0 h wound width] × 100% [16].

Matrigel angiogenesis assay

Matrigel (Shanghai Shanran Biotechnology Co., Ltd.) was maintained in a stationary state at 4°C overnight, and became yellow and gelatinous the following day. Subsequently, 70 μl Matrigel (0.5 mmol/l) was added to a pre-cooled 96-well plate. Cell suspensions (1x10⁵ cells/ml) were inoculated in the Matrigel-coated culture well for 18 h. A total of three randomly selected visual fields were visualized in each well. The average length and number of tube-like structures in each visual field were calculated and recorded [17].

Transendothelial permeability evaluation

The endothelial function of HCMECs was detected using the CultreCoat® 24 Well In Vitro Vascular Permeability kit (Trevigen, Inc.) according to the manufacturer’s protocol. Briefly, cells were seeded onto a membrane in complete growth medium to allow proliferation and adhesion prior to treatment. FITC-Dextran was added and allowed to permeate into the
plate well through defective cell adhesion. The fluorescence intensity was measured using a microplate reader [18].

**Western blot**

Protein samples were prepared using lysis buffer, then loaded and electrophoresed with the running gel. Transfer buffer was used for protein transferring. Following blocking with 5% BSA, the membranes were incubated with the following primary antibodies: Anti-zonula occludens-1 (ZO-1; cat. no. 5406; Cell Signaling Technology, Inc.), anti-vascular endothelial (VE)-cadherin (cat. no. 2158), anti-Claudin-5 (cat. no. sc-374,221; Santa Cruz Biotechnology, Inc.) and GAPDH (cat. no. 5174). Subsequently, the membranes were incubated with a Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) secondary antibody (cat. no. ab150077; Abcam). Protein blots were visualized using chemiluminescence.

**Statistical analysis**

Comparisons among among 3 and more groups were analyzed using one-way ANOVA followed by Tukey’s post hoc test and only two groups were compared with unpaired t test. Statistical analyses were performed using GraphPad Prism software (version 7; GraphPad Software, Inc.). All values are presented as the mean ± standard deviation, and P < 0.05 was considered to indicate a statistically significant difference.

**Results**

**REM preconditioning enhances HCMC viability after H/R**

The effect of REM on HCMC viability in the absence of H/R was examined first. Cells treated with different concentrations of REM exhibited no significant alterations in cell viability (Figure 1a). However, under H/R conditions, HCMCs pre-treated with REM exhibited a concentration-dependent increase in viability compared with the model group (Figure 1b).

**REM preconditioning promotes the migration and angiogenesis of HCMCs after H/R**

The effect of REM on HCMC migration during H/R was assessed. Cell migration in the H/R group was significantly slower compared with that in the control group, and REM increased cell migration during H/R in a concentration-dependent manner (Figure 2a). Additionally, the Matrigel angiogenesis assay results showed that H/R impaired the tube formation ability of HCMCs in the model group, whereas pretreatment with REM improved HCMC tube formation in a concentration-dependent manner (Figure 2b).

**REM preconditioning decreases the permeability of HCMCs after H/R and upregulates tight junction protein expression**

The in vitro vascular permeability assay results showed a notable increase in fluorescence intensity in the model group compared with that in the

---

**Figure 1. REM preconditioning enhances the viability of HCMCs after H/R** The viability of HCMCs pre-treated with different concentrations of REM, detected under normal conditions (a) and under H/R conditions (b), detected with CCK-8. *P < 0.05, ** ** **P < 0.001 vs Control.
control group, whereas pretreatment with REM gradually reduced the fluorescence intensity with increasing concentrations (Figure 3a). The aforementioned results indicated that REM preconditioning improved the endothelial barrier function of HCMCs under H/R conditions. Furthermore, a decline in the expression levels of tight junction proteins (ZO-1, VE-cadherin and Claudin-5) was detected via western blotting in H/R-stimulated HCMCs, which also demonstrated that protein

![Figure 2. REM preconditioning promotes the migration and angiogenesis of HCMCs after H/R](image)

The migration (a) and tube-like structure formation (b) abilities of HCMCs pre-treated with different concentrations of REM following H/R, detected by wound healing assay and Matrigel angiogenesis assay. **P < 0.01, ***P < 0.001 vs Control.

![Figure 3. REM preconditioning decreases the permeability of HCMCs after H/R and upregulates tight junction protein expression](image)

(a) The permeability of HCMCs pre-treated with different concentrations of REM following H/R, detected by in vitro vascular permeability kit. The intensity of fluorescence reflects the degree of cell permeability. (b-c) The expression of tight junction proteins in HCMCs pre-treated with different concentrations of REM following H/R, detected by western blot. *P < 0.05, **P < 0.01, ***P < 0.001 vs Control.
expression levels in cells pretreated with REM gradually increased with increasing concentrations (Figure 3b and c).

**REM preconditioning regulates the PI3K/Akt/HIF-1α signaling pathway in HCMECs**

To identify the association between REM and the PI3K/Akt/HIF-1α signaling pathway, western blotting was performed to detect the expression of relevant proteins [phosphorylated (p)-PI3K/PI3K, p-Akt/Akt, HIF-1α and VEGF] in the control, model and REM treatment groups. Protein expression levels were all much lower in the model group compared with those in the control group, and REM pretreatment elevated the expression levels in HCMECs stimulated with H/R in a concentration-dependent manner (Figure 4).

**PI3K/Akt inhibition rescues REM-induced HCMEC viability, migration and angiogenesis after H/R**

The aforementioned results demonstrated the protective effect of REM on HCMECs at a concentration of 2.5 μM; therefore, 2.5 μM REM was used for the subsequent experiments. To investigate whether REM benefited HCMEC function during H/R via the PI3K/Akt/HIF-1α signaling pathway, cells were pretreated with the PI3K/Akt inhibitor LY294002 for further experiments. REM-induced increases in HMEC viability during H/R were decreased in the presence of LY294002 pretreatment (Figure 5a). Pretreatment with LY294002 also rescued REM-induced HCMEC migration during H/R (Figure 5b). Additionally, the REM-induced tube formation abilities of H/R-stimulated HCMECs were significantly impaired in the presence of LY294002 (Figure 5c).

**PI3K/Akt inhibition reverses the protective effect of REM preconditioning on HCMEC endothelial barrier function after H/R**

To further examine the role of PI3K/AKT signaling pathway in the protective effect of REM preconditioning on HCMEC endothelial barrier function, in vitro vascular permeability assays showed that H/R-stimulated HCMECs treated with REM displayed upregulated fluorescence intensity in the presence of LY294002 compared with the REM + H/R group (Figure 6a). REM-induced upregulation of the expression of tight junction proteins (ZO-1, VE-cadherin and Claudin-5) was also downregulated by LY294002 pretreatment in HCMECs following H/R (Figure 6b and c).

---

Figure 4. REM preconditioning regulates the PI3K/Akt/HIF-1α signaling pathway in HCMECs The expression of relevant proteins to the PI3K/Akt/HIF-1α signaling pathway in HCMECs pre-treated with different concentrations of REM following H/R, detected by western blot. *P < 0.05, ** P < 0.01, ***P < 0.001 vs Control.
Figure 5. PI3K/Akt inhibition rescues REM-promoted HCMEC viability, migration and angiogenesis after H/R The viability (a), migration (b) and tube-like structure formation (c) of HCMECs treated with REM following H/R in the presence of LY294002, correspondingly detected by CCK-8, wound healing and Matrigel angiogenesis assay. ***P < 0.001 vs Control; ##P < 0.01, ### P < 0.001 vs Model; @P < 0.05, @@@P < 0.001 vs H/R+ REM.

Figure 6. PI3K/Akt inhibition reverses the protective effect of REM preconditioning on HCMEC endothelial barrier function after H/R (a) The permeability of HCMECs treated with REM following H/R in the presence of LY294002, detected by in vitro vascular permeability kit. The intensity of fluorescence reflects the degree of cell permeability. (b-c) The expression of tight junction proteins in HCMECs treated with REM following H/R in the presence of LY294002, detected by western blot. ***P < 0.001 vs Control; ### P < 0.001 vs Model; @P < 0.05, @@P < 0.01, @@@P < 0.001 vs H/R+ REM.
Discussion

Myocardial ischemia is a condition in which insufficient blood and oxygen supply to the myocardial tissues results in abnormal energy metabolism of the myocardium and an inability to support the normal functioning of the heart [19]. With improvements in living standards, the prevalence of myocardial ischemia in China has been increasing year by year in the past decades, and it has become a frequently occurring disease in the elderly [20]. There are also clinical cases of young patients between the ages of 20 and 30 showing signs of myocardial ischemia or being diagnosed with coronary heart disease, the most common cause of myocardial ischemia [21,22]. Microvascular obstruction, damaged myocardium, endothelial edema and endothelial sloughing are the frequent outcomes and aggravators of myocardial infarction [23]. Therefore, repairing the function of cardiac microvascular endothelial cells is important for the treatment of myocardial ischemia.

REM is a mu-opioid receptor agonist of fentanyl that is primarily used as an intra-operative analgesic. The analgesic effect of REM is strong enough to be used in a variety of surgeries, including coronary artery bypass surgery [12,24]. Emerging evidence in recent years suggested that REM may display cardioprotective effects in view of reports on how the activation of opioid receptors could potentially protect against myocardial I/R injury in myocardial salvage [25–27]. In addition, a previous study demonstrated that REM pretreated human cardiomyocytes display an improved resistance to cell senescence and necrosis induced by hypoxia [28]. In a rat model of isoproterenol-induced myocardial injury, REM effectively improved cardiac dysfunction, lipid peroxidation and immune disorder by blocking the JNK/NF-κB p65 pathway [29]. Moreover, it has been reported that postconditioning with REM could activate autophagic reflux blocked by H/R in H9c2 cardiomyocytes, thus preventing H/R-induced cardiomyocyte injury [30]. The present study first established the safety of using REM in HCMECs and no cytotoxicity was observed. The results also demonstrated that REM preconditioning increased HCMEC viability under H/R conditions.

Microvascular dysfunction in cardiac I/R injury and various other diseases generally presents as inflammation, reduced microvascular flow and impaired angiogenic and self-repairing abilities [31,32]. Among these, the abnormal microvascular angiogenesis involves insufficient cardiac microvascular endothelial cell migration [33]. In the present study, REM preconditioning promoted the migration of HCMECs and improved their ability to form tube-like structures under H/R conditions. In myocardial I/R injury, insufficient secretion of endothelium-derived relaxing factor and excessive secretion of endothelin-1 in myocardium microvascular endothelial cells leads to increased cell permeability [34,35], further resulting in microvascular endothelial edema, which is part of the pathophysiological transition of reversible ischemic myocardial injury to irreversible injury. ZO-1, VE-cadherin and Claudin-5 are important mediators of endothelial adherence junction and angiogenesis, and are vital in maintaining the blood-brain barrier balance in ischemic stroke [36–38]. The results of the present study showed that REM preconditioning improved the endothelial barrier function by decreasing cell permeability and upregulating the expression of ZO-1, VE-cadherin and Claudin-5. The aforementioned results collectively demonstrate the beneficial effects of REM on the viability, migration, angiogenesis and permeability of HCMECs following H/R.

According to a previous study, REM can repair post-traumatic osteoarthritis cartilage damage by inhibiting PI3K/Akt/NF-κB phosphorylation, reducing cartilage matrix degradation and inhibiting IL-1β-induced apoptosis of articular chondrocytes [39]. Mice preconditioned with REM have been reported to display a much lower risk of myocardial injury following I/R procedures, whereas hyperglycemia-induced oxidative stress could diminish REM cardioprotection by damaging the Caveolin-3-regulated PI3K/Akt and JAK2/Stat3 signaling pathways [14]. Additionally, PI3K/Akt regulated by Ginsenoside Re could serve an alleviative role in high glucose-induced RF/6A retinal endothelial cell injury by inhibiting the HIF-1α/VEGF signaling pathway [40]. More importantly, long non-coding RNA small nucleolar RNA host gene 1-activated HIF-1α/VEGF has
been found to increase the expression of VE-cadherin and MMP2, and facilitate the proliferation and angiogenesis of HUVECs following H/R [41]. Therefore, PI3K/Akt/HIF-1α may serve as a signaling pathway in the mechanism underlying REM-mediated cardioprotection against H/R-induced HCMEC injury. After identifying that REM regulated the expression of PI3K/Akt/HIF-1α in HCMECs, the results of the present study further confirmed that inhibiting PI3K/Akt signaling rescued the ameliorative effects of REM on H/R-induced HCMEC injury by decreasing cell viability, migration and angiogenesis, impairing endothelial barrier function and downregulating the expression of tight junction proteins.

In summary, REM pretreatment ameliorated H/R-induced HCMEC dysfunction by regulating the PI3K/Akt/HIF-1α signaling pathway. The present study elucidated the mechanism underlying the cardioprotective effect of REM in H/R-induced HCMEC injury. REM may serve as a novel adjuvant in the treatment of myocardial ischemia and be used for the management of cardiac ischemia/reperfusion injury.

Research highlights

Remifentanil ameliorated HCMECs dysfunction
Remifentanil targeted the PI3K/Akt/HIF-1α pathway
Remifentanil may become a novel adjuvant in the treatment of myocardial ischemia

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

[1] Shao C, Wang J, Tian J, et al. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020;1177:1–36. PubMed PMID: 32246442.
[2] Matta A, Bouisset F, Lhermusier T, et al. Coronary artery spasm: new insights. J Interv Cardiol. 2020;2020:5894586. PubMed PMID: 32508542; PubMed Central PMCID: PMCPMC7245659.
[3] Pagliaro BR, Cannata F, Stefanini GG, et al. Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev. 2020;25(1):53–65. PubMed PMID: 31332663.
[4] Jia S, Liu Y, Yuan J. Evidence in guidelines for treatment of coronary artery disease. Adv Exp Med Biol. 2020;1177:37–73. PubMed PMID: 32246443.
[5] Binder A, Ali A, Chawla R, et al. Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev Cardiovasc Ther. 2015;13(9):1045–1057. PubMed PMID: 26202544.
[6] Du J, Li Y, Zhao W. Autophagy and Myocardial Ischemia. Adv Exp Med Biol. 2020;1207:217–222. PubMed PMID: 32671750.
[7] Shi B, Ma M, Zheng Y, et al. mTOR and beclin1: two key autophagy-related molecules and their roles in myocardial ischemia/reperfusion injury. J Cell Physiol. 2019;234(8):12562–12568. PubMed PMID: 30618070.
[8] Wang J, Toan S, Zhou H. New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis. 2020;23(3):299–314. PubMed PMID: 32246225.
[9] Gao XM, Su Y, Moore S, et al. Relaxin mitigates microvascular damage and inflammation following cardiac ischemia-reperfusion. Basic Res Cardiol. 2019;114(4):30. PubMed PMID: 31218471.
[10] Rios-Navarro C, Marcos-Garcés V, Bayes-Genis A, et al. Microvascular obstruction in st-segment elevation myocardial infarction: looking back to move forward. focus on CMR. J Clin Med. 2019;8(11):1805. PubMed PMID: 31661823; PubMed Central PMCID: PMCPMC6912395.
[11] Nowoczn M, Marie N, Coulbault L, et al. Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor. Neuropharmacology. 2013;73:368–379. PubMed PMID: 23792280.
[12] Greco M, Landoni G, Biondi-Zoccai G, et al. Remifentanil in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2012;26(1):110–116. PubMed PMID: 21820920.
[13] Subramaniam K, Sciortino C, Ruppert K, et al. Remifentanil and perioperative glycaemic response in cardiac surgery: an open-label randomised trial. Br J Anaesth. 2020;124(6):684–692. PubMed PMID: 32247539.
[14] Lei S, Su W, Xia ZY, et al. Hyperglycemia-induced oxidative stress abrogates remifentanil preconditioning-mediated cardioprotection in diabetic rats by impairing caveolin-3-Modulated PI3K/Akt and JAK2/STAT3 signaling. Oxid Med Cell Longev. 2019;2019:9836302. PubMed PMID: 31583053; PubMed Central PMCID: PMCPMC6748204.
[15] Gao F, Wu H, Wang R, et al. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2. Bioengineered. 2019;10(1):1–12. PubMed PMID: 30836864; PubMed Central PMCID: PMCPMC6527069.
[16] Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of
ERK signaling. Oncotarget. 2017;8(20):33694–33703. PubMed PMID: 28402270; PubMed Central PMCID: PMCPMC5464903.

[17] Shang J, Gao ZY, Zhang LY, et al. Over-expression of JAZF1 promotes cardiac microvascular endothelial cell proliferation and angiogenesis via activation of the Akt signaling pathway in rats with myocardial ischemia-reperfusion. Cell Cycle. 2019;18(14):1619–1634. PubMed PMID: 31177938; PubMed Central PMCID: PMCPMC6619954.

[18] Li Z, Yin M, Zhang H, et al. BMX represses thrombin-PAR1-mediated endothelial permeability and vascular leakage during early sepsis. Circ Res. 2020;126(4):471–485. PubMed PMID: 31910739; PubMed Central PMCID: PMCPMC7035171.

[19] Ambrose JA. Myocardial ischemia and infarction. J Am Coll Cardiol. 2006;47(11Suppl):D13–7. PubMed PMID: 16750715.

[20] Zhao M, Klipstein-Grobusch K, Wang X, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0175947. PubMed PMID: 28426793; PubMed Central PMCID: PMCPMC5398555.

[21] Vaccarino V, Sullivan S, Hammadah M, et al. mental stress-induced-myocardial ischemia in young patients with recent myocardial infarction: sex differences and mechanisms. Circulation. 2018;137(8):794–805. PubMed PMID: 29459465; PubMed Central PMCID: PMCPMC5822741.

[22] Safdar B, Spatz ES, Dreyer RP, et al. Presentation, Clinical Profile, and Prognosis of Young Patients With Myocardial Infarction Without Nonobstructive Coronary Arteries (MINOCA): results From the VIRGO Study. J Am Heart Assoc. 2018;7(13). PubMed PMID: 29954744; PubMed Central PMCID: PMCPMC6064896. 10.1161/JAHA.118.009174

[23] Lindner JR. Microvascular Impairment After Myocardial Infarction: it is Not Just About Obstruction. Circ Cardiovasc Imaging. 2020;13(6):e011083. PubMed PMID: 32527158; PubMed Central PMCID: PMCPMC7491571.

[24] Cohen J, Royston D. Remifentanil. Curr Opin Crit Care. 2001;7(4):227–231. PubMed PMID: 11571418.

[25] Irwin MG, Wong GT. Remifentanil and opioid-induced cardioprotection. J Cardiothorac Vasc Anesth. 2015;29(Suppl 1):S23–6. PubMed PMID: 26025042.

[26] Tanaka K, Kersten JR, Riess ML. Opioid-induced cardioprotection. Curr Pharm Des. 2014;20(36):5696–5705. PubMed PMID: 24502571; PubMed Central PMCID: PMCPMC4216587.

[27] Kim JM, Jang YH, Kim J. Morphine and remifentanil-induced cardioprotection: its experimental and clinical outcomes. Korean J Anesthesiol. 2011;61(5):358–366. PubMed PMID: 22148082; PubMed Central PMCID: PMCPMC3229012.

[28] Lewinska A, Adamczyk-Grochala J, Bloniarz D, et al. Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro. Aging (Albany NY). 2020;12(14):13924–13938. PubMed PMID: 32584786; PubMed Central PMCID: PMCPMC7425462.

[29] Zhou Q, Song J, Wang Y, et al. Remifentanil attenuates cardiac dysfunction, lipid peroxidation and immune disorder in rats with isoproterenol-induced myocardial injury via JNK/NF-KB p65 inhibition. Ann Transl Med. 2020;8(8):551. PubMed PMID: 32411774; PubMed Central PMCID: PMCPMC7214888.

[30] Zuo Y, Zhang J, Cheng X, et al. Enhanced autophagic flux contributes to cardioprotection of remifentanil postconditioning after hypoxia/reoxygenation injury in H9c2 cardiomyocytes. Biochem Biophys Res Commun. 2019;514(3):953–959. PubMed PMID: 31092327.

[31] Shi Y, Vanhoucke PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9(5):434–449. PubMed PMID: 28044409.

[32] Yu H, Kalogiannis T, Korthuis RJ. Reactive species-induced microvascular dysfunction in ischemia/reperfusion. Free Radic Biol Med. 2019;135:182–197. PubMed PMID: 30849489; PubMed Central PMCID: PMCPMC6503659.

[33] Zhu T, Yao Q, Wang W, et al. iNOS induces vascular endothelial cell migration and apoptosis via autophagy in ischemia/reperfusion injury. Cell Physiol Biochem. 2016;38(4):1575–1588. PubMed PMID: 27082814.

[34] Filep JG, Sirois MG, Foldes-Filep E, et al. Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol. 1993;109(3):880–886. PubMed PMID: 8358577; PubMed Central PMCID: PMCPMC2175619.

[35] Tolins JP, Shultz PJ, Raji L. Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Update on humoral regulation of vascular tone. Hypertension. 1991;17(6 Pt 2):909–916. PubMed PMID: 2045172.

[36] Tornavaca O, Chia M, Dufton N, et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015;208(6):821–838. PubMed PMID: 25753039; PubMed Central PMCID: PMCPMC4362456.

[37] Jiao H, Wang Z, Liu Y, et al. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci. 2011;44(2):130–139. PubMed PMID: 21318404.
[38] Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 2013;26(5):441–454. PubMed PMID: 24044891.

[39] Ke H, Mou X, Xia Q. Remifentanil repairs cartilage damage and reduces the degradation of cartilage matrix in post-traumatic osteoarthritis, and inhibits IL-1beta-induced apoptosis of articular chondrocytes via inhibition of PI3K/AKT/NF-kappaB phosphorylation. Ann Transl Med. 2020;8(22):1487. PubMed PMID: 33313232; PubMed Central PMCID: PMCPMC7729373.

[40] Xie W, Zhou P, Qu M, et al. Ginsenoside re attenuates high glucose-induced RF/6A injury via regulating PI3K/AKT inhibited HIF-1alpha/VEGF signaling pathway. Front Pharmacol. 2020;11:695. PubMed PMID: 32528282; PubMed Central PMCID: PMCPMC7253708.

[41] Liang S, Ren K, Li B, et al. LncRNA SNHG1 alleviates hypoxia-reoxygenation-induced vascular endothelial cell injury as a competing endogenous RNA through the HIF-1alpha/VEGF signal pathway. Mol Cell Biochem. 2020;465(1–2):1–11. PubMed PMID: 31792649.